Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Phenylbutyrate→

Phenylbutyrate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1821-12-1
Molecular formula
C10H12O2
Molecular weight
164.2 g/mol
Drug class
Ammonia-scavenging nitrogen-binding agenttreatment for urea-cycle disorders
Mechanism of action
Phenylbutyrate is metabolised to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This nitrogen-containing conjugate is excreted in urine, providing an alternative pathway for waste-nitrogen removal and lowering plasma ammonia.
Indications / reported uses
  • Adjunctive chronic management of patients with urea-cycle disorders involving deficiencies of carbamoyl phosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase, in conjunction with dietary management and other indicated therapy.

Sources: https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d08fd548-7eb8-4f6f-b664-b0fff6f30065&type=display · https://pmc.ncbi.nlm.nih.gov/articles/PMC3488504/ · DailyMed

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Phenylbutyrate Environmental Risk Assessment (ERA) (the Phenylbutyrate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.